BioWorld

Aug. 27, 2008

Indevus Closes $105M Note Deal Backed by Sanctura Royalties

Indevus Pharmaceuticals Inc. joined the ranks of biotechs leveraging royalty streams to access nondilutive financing. (BioWorld Today) Read More

QLT Anticipates Excess of Cash Following Atrigel, Other Deals

Restarted Pharmalink Generates Promising Phase III Data in PPS

Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...